Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII

American Journal of Obstetrics and Gynecology

Volumn 186, Issue 1, 2002, Pages 44-48

  Van Rooijen, Marianne ^a   Von Schoultz, Bo ^a   Silveira, Angela ^a   Hamsten, Anders ^a   Bremme, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Desogestrel; Factor VII; Levonorgestrel; Oral contraceptives; Plasma lipoproteins

Indexed keywords

BLOOD CLOTTING FACTOR 7; CHOLESTEROL; DESOGESTREL; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCOAGULABILITY; LIPOPROTEIN BLOOD LEVEL; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036153363     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.119179     Document Type: Article

References (25)

1. Venous embolism among new users of different oral contraceptives
2. The risk of venous thromboembolism associated with low oestrogen oral contraceptives
3. Oestrogen and the risk of coagulopathy
4. Potency of different estrogen preparations
5. Biological effects of various doses of conjugated equine estrogens in postmenopausal women
6. Effect of oral contraceptives on haemostatic variables
7. Effect of progestogens on haemostasis
8. Blood coagulation and oral contraceptives
9. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
10. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
11. Lipoprotein fractionation
12. Metabolic changes during treatment with two different progestogens
13. Hemostatic system changes induced by 50 microgram and 30 microgram estrogen/progestogen oral contraceptives. Modification of oestrogen effects by levonorgestrel
14. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
15. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
16. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphism - The Leiden Thrombophilia Study (LETS)
17. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins
18. Plasma lipoproteins enhance tissue factor-independent factor VII activation
19. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway
20. Safety evaluation of modern oral contraceptive. Effects on lipoprotein and carbohydrate metabolism
21. Interactions amongst insulin, lipoproteins, and haemostatic function relevant to coronary heart disease
22. Lipoprotein metabolism and thrombosis
23. A randomised comparison of the effect of oral versus transdermal 17 beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipids
24. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations
25. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys